Search Results - dlbcl

4 Results

Sort By:

Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs)

Abstract: Chimeric antigen receptors (CARs) combine an antibody-based binding domain (and single chain fragment variable region, scFv) with T cell receptor signaling domains (CD3 zeta with a costimulatory domain, typically CD28 or 41BB). When T cells express CARs, they are activated in a major histocompatibility complex- (MHC) independent manner to...

Published: 4/8/2024 | Inventor(s): Terry Fry, Crystal Mackall, Rimas Orentas, Haiying Qin, Waleed Haso

Keywords(s): Acute Lymphoblastic Leukemia, ALL, BISPECIFIC, Bivalent, CAR, CD19, CD22, Diffuse Large B-Cell Lymphoma, DLBCL, Dual-Specific Chimeric Antigen Receptors, Fry, Oncology, Pediatric Leukemia, Pediatric Lymphoma

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Dual Specific Anti-CD22 Anti-CD19 Bicistronic Chimeric Antigen Receptors (CARs)

Abstract: Treatment of B-cell acute lymphoblastic leukemia (ALL) and lymphoma using chimeric antigen receptors (CARs) targeting B-cell surface protein CD19 has demonstrated impressive clinical results in children and young adults. Despite the promising results from CD19 CAR therapy, up to 40% of patients, who initially achieve remission, eventually...

Published: 8/14/2024 | Inventor(s): Haiying Qin, Terry Fry, Crystal Mackall

Keywords(s): Acute Lymphoblastic Leukemia, ALL, BICISTRONIC, CAR, CD19, CD22, Diffuse Large B-Cell Lymphoma, DLBCL, Dual-Specific Chimeric Antigen Receptors, Fry, Oncology, Pediatric Leukemia, Pediatric Lymphoma

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration

Methods of Treating Diffuse Large B Cell Lymphoma Based on Particular Genetic Subtype (LymphGen) - A Genetic Classifier to Aid in the Molecular Diagnosis and Treatment of Diffuse Large B-cell Lymphoma

Abstract: The development of precision medicine approaches for DLBCL (Diffuse Large B Cell Lymphoma) is complicated by its genetic, phenotypic and clinical heterogeneity. Current classification methods do not fully explain the observed differences in clinical outcomes to current chemotherapy and targeted therapy. Therefore, better analytical methods...

Published: 8/14/2024 | Inventor(s): George Wright, Louis Staudt, Calvin Johnson, Da Wei Huang

Keywords(s): Diffuse Large B Cell Lymphoma, DLBCL, LymphGen, Precision Medicine, PREDICTIVE, Staudt

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Diagnostics

Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens

Abstract: Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common...

Published: 4/8/2024 | Inventor(s): Louis Staudt, Lisa Rimsza, David Scott, George Wright, Anja Mottok, Christian Steid, Elaine Jaffe, Randy Gascoyne, Elias Guerri, Elias Guerri, Elias Guerri, Andreas Rosenwald, Kai Fu, Timothy Greiner, Erlend Smeland, Jan Delabie, Rita Braziel, Wing Chan, Joo Song, Dennis Weisenburger, German Ott, James Cook

Keywords(s): assay, Diffuse Large B Cell Lymphoma, DLBCL, FFPE, Formalin-fixed, GENE EXPRESSION, paraffin-embedded biopsies, PMBCL, Primary Mediastinal Large B Cell Lymphoma, Staudt

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Diagnostics